AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03881059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose B
Description: Participants will receive BMS-986165 dose B QD.
Study NCT03881059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive ustekinumab SQ injection QD.
Study NCT03881059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ustekinumab Placebo
Description: Participants will receive ustekinumab SQ matching placebo QD
Study NCT02204293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
Study NCT02204293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canakinumab
Description: Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
Study NCT02204293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered subcutaneously.
Study NCT01932138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced CHW intervention
Description: The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention.
Study NCT01932138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
Study NCT00827151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen
Description: Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
Study NCT02293837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
Study NCT02293837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
Study NCT02293837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
Study NCT02293837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
Study NCT01757067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC ablation
Description: This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
Study NCT01223222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LTX-109
Description: Topical administration. 3 times daily. 5 days.
Study NCT01223222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109
Description: Topical administration. 3 times daily. 5 days.
Study NCT00849680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
Description: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
Study NCT00849680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
Description: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
Description: Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)
Study NCT00849680 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
Description: Placebo to the MRKAd5 HIV-1 gag vaccine.
Study NCT00786474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution, dosage determined by weight, self-administered by patient twice a day
Study NCT00786474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
Study NCT02926508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno (BGOS)
Description: The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
Study NCT02926508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
Study NCT03411889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scanning
Description: MRI scanning during tear drainage
Study NCT02663375 — intervention group
Intervention type: DEVICE
Intervention: ACURATE TA™ Transapical Aortic Bioprosthesis
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
Study NCT02631811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive /palliative care intervention
Description: patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
Study NCT02532322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Study NCT02532322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Study NCT01534455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib + 1,23 mg Eribulin
Description: Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
Study NCT01534455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib + 1,76 mg Eribulin
Description: Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
Study NCT02521324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DGB2
Description: DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
Study NCT02521324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DGB2
Description: DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
Study NCT02685371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Breathing
Description: Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
Study NCT03759366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered by IV infusion.
Study NCT01561456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Study NCT04497350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
Study NCT04497350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
Study NCT01523704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTRONIK Home Monitoring System
Description: Home Monitoring system transfers implantable device's data to the main server via internet.
Study NCT01561456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Study NCT02251340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eczema Care Plan
Study NCT04529811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation
Study NCT04529811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02702336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EYTO-kids
Description: To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: 5mg in 1 ml normal saline
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine 2%
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine 0.5%
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronidase powder
Description: 1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
Study NCT03243500 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: hyaluronidase powder
Description: 1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
Study NCT03243500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: per-caruncular peribulbar injection
Description: The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
Study NCT01523704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTRONIK Home Monitoring System with In-office Follow-up
Study NCT04312282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel orally on Day 1 of a 21-day cycle
Study NCT03243500 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: per-caruncular peribulbar injection
Description: The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
Study NCT04312282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
Study NCT04312282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
Study NCT00568256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind/Body Courses
Description: 8-week Mind/Body course held once a week for 2 hours at a time.
Study NCT00568256 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind/Body Courses
Description: 8-week Mind/Body course held once a week for 2 hours at a time.
Study NCT03946670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is being administered i.v.
Study NCT03946670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is being administered i.v.
Study NCT03946670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Description: Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
Study NCT03946670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypomethylating agents
Description: Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
Study NCT03283917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03283917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03283917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT02506881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Study NCT03329248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovaza
Description: Omega-3-acid ethyl esters
Study NCT03329248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03329248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT01921738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin gel
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
Study NCT01921738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
Study NCT01921738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
Study NCT01921738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
Study NCT03535194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT03535194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT03535194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Administered SC